113 private equity firms lined up for a piece of Changxin Technology’s (CXMT) IPO. Their collective bid: 1.75 billion yuan. Their reward: 9% of the total allocation. The remaining 91% went to state-backed A-class investors. This is not a market pricing assets. This is a government pricing strategy.
I do not trust the pitch; I audit the structure. And the structure here reveals a critical imbalance: private capital, with its sharp risk sensors, took a token position. Public capital, with its mandate to advance national policy, shouldered the load. The allocation ratio screams one thing—this is a political instrument disguised as a public offering.
Context: Changxin Technology is China’s only homegrown DRAM manufacturer. It sits at the intersection of the US-China tech war and the global memory oligopoly dominated by Samsung, SK Hynix, and Micron. The IPO, expected to raise tens of billions of yuan, is intended to fund capacity expansion, process node upgrades, and ostensibly, a push into HBM (High Bandwidth Memory). The narrative is seductive: “national champion,” “self-sufficiency,” “break the monopoly.”
But emotion is a variable I exclude from the equation. I examine the code—the underlying mechanics of technology, supply chain, and financial viability. What I find is a project whose survival hinges not on innovation, but on an unresolved geopolitical variable. The IPO is not a growth investment; it is a call option on diplomatic détente.
Core: The Systematic Teardown
1. Technology Gap: 3–4 Years, 2–3 Nodes Behind
CXMT’s current mainstream node is 17nm (their 10G2). The industry leader, Samsung and SK Hynix, are mass-producing at 1β (roughly 12–13nm). The difference is not just a number. It represents a 3–4 year lag in transistor density, power efficiency, and cost per bit. In DRAM, where margins are razor-thin and competition is driven by yield and scale, this gap is existential.
Their yield is estimated at 75–85%. Industry leaders operate above 90%. This 5–15% yield gap translates directly into higher costs per die. CXMT must sell at market prices but produce at higher cost—a formula for negative gross margins. The only way to compensate is through sheer volume, but volume requires equipment.
2. Supply Chain: A Single Point of Failure
The most critical component in DRAM fabrication is the immersion deep ultraviolet (DUV) lithography scanner. The only supplier capable of producing the necessary systems (e.g., ASML NXT:1980i and beyond) is Dutch. CXMT is prohibited from purchasing these machines under US export controls. ASML cannot deliver. Tokyo Electron’s etchers are similarly restricted.
CXMT’s current capacity of ~100–120k wafers per month at its Hefei fab runs on machines it acquired before the tightening of controls. Its expansion plans for Phase 2 and Phase 3 are indefinitely stalled. It has the money—IPO proceeds—but cannot convert capital into capacity. In blockchain terms, this is a smart contract with a fatal external dependency: the oracle (equipment supply) can be turned off at any time, and there is no fallback.
Domestic alternatives? Shanghai Micro Electronics Equipment’s (SMEE) DUV lithography is generations behind, incapable of patterning the critical layers for modern DRAM. The equipment gap is not bridgeable within five years. CXMT’s supply chain vulnerability is not a risk; it is a guarantee of stagnation unless the export controls are lifted.
3. Financial Viability: Negative Margins, No Free Cash Flow
CXMT’s gross margin is negative or near zero. Even in a strong DRAM upcycle (which we are currently in, with prices recovering from 2023 lows), the company struggles to break even. Why? High depreciation from previous capital spending, low yield, and the need to price aggressively to win orders from domestic customers like Huawei.
Its operating cash flow is negative. Free cash flow is deeply negative due to ongoing capex. The IPO is not fuel for growth; it is life support. Without it, CXMT would likely face a liquidity crisis within two years.
Valuation metrics confirm the disconnect. Price-to-sales ratios above 5x, while Samsung trades at 2x. Price-to-book is inflated. The company is unprofitable, so PE is meaningless. The only way to justify this valuation is to treat CXMT as a strategic asset with a government backstop—a call option on China’s willingness to subsidize indefinitely.
4. The “HBM Mirage”
HBM is the high-margin, high-growth segment of the memory market, driven by AI training chips. CXMT has no HBM capability. Its technology is limited to DDR4, DDR5, and LPDDR5. To enter HBM, it would need advanced packaging (TSV, micro-bumps, hybrid bonding) and a logic chip partner like Nvidia or AMD, both of which are blocked by US sanctions from working with CXMT.
The IPO narrative may hint at HBM expansion, but the reality is that CXMT is 5+ years behind SK Hynix and Samsung in HBM. By the time CXMT could potentially produce HBM2E, the market will be on HBM4. The window is closed.
Contrarian: What the Bulls Get Right
I am not an ideologue. The bull case has real pillars.
First, domestic demand is robust. China’s server, PC, and smartphone OEMs—especially Huawei—face increasing pressure to source memory from non-US-aligned suppliers. This creates an artificial but durable demand floor for CXMT’s products. Even with inferior specs, domestic customers will buy because they must.
Second, the DRAM market is currently in a cyclical upswing. Prices have been rising since late 2023 and are expected to continue into 2025. This tailwind will temporarily improve CXMT’s margins, possibly even into positive territory. The IPO is timed to capture this window.
Third, the Chinese government has a strong incentive to keep CXMT alive. The “National Team” (state funds, policy banks) will provide ongoing support. The IPO allocation itself—91% to A-class institutional investors—demonstrates that Beijing is committed. This is not a commercial enterprise; it is a strategic asset. Failure is not an option politically.
These factors give CXMT a breathing room of 3–5 years. But they do not solve the core equation: without unrestricted access to advanced lithography, the technology gap will widen, not close. The bull case assumes that export controls will eventually loosen or that domestic equipment will miraculously leapfrog. Both assumptions are speculative at best.
Takeaway: Audit the Structure, Not the Pitch
Liquidity is a mirage; solvency is the only truth. CXMT’s IPO is a liquidity event, not a solvency fix. The company remains unprofitable, technologically dependent, and geopolitically hostage. The 113 private funds that took only 9% of the allocation understand this. They placed small bets to maintain relationships, not because they believe the math works.
Liang Wenfeng’s High-Flyer Quant—the largest private participant—likely views this as a policy-driven trade, not a fundamental investment. His 175 million yuan may be a strategic gesture to signal alignment with national priorities, not a conviction in CXMT’s technology.
In crypto, we audit the smart contract. In traditional finance, we audit the balance sheet and the supply chain. CXMT’s smart contract has a fatal bug: its most critical function (equipment procurement) cannot execute under current conditions. No amount of state funding can rewrite the laws of physics or the geopolitical reality.
Emotion is a variable I exclude. The takeaway is cold: CXMT’s IPO is not an investment opportunity. It is a subsidy mechanism disguised as equity. The only real question is how long the government can keep the protocol running before the necessary external dependency breaks the chain.
Skepticism is not cynicism; it is the only responsible stance when the system’s core assumption is unproven. Changxin’s technology is real. Its necessity is real. But its viability under the current geopolitical regime is not. The market knows this. The allocation numbers tell the story. Now it is up to the reader to decide whether they are betting on technology or on politics.